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ACE inhibitors are often prescribed in the treatment of hypertension, heart failure and kidney disease. These drugs are 
on the Essential Drugs List, and are therefore used at primary to tertiary health care levels in South Africa. Angioedema 
is considered a rare, but potentially fatal side-effect of this agent, with a reported incidence of 0.1–0.2% worldwide.1 Its 
incidence in the South African population is, however, unknown. 
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Case reports
We report on two cases that were recently referred for 
medico-legal autopsy at our mortuary, in which the cause of 
death was ascertained to be “asphyxia due to angioedema 
of the tongue and upper airway, due to ACE inhibitor 
therapy”.
The subjects were on treatment with the ACE inhibitors, 
enalapril and perindopril, for approximately 10 months and 4 
years, respectively. No personal or family history of allergies 
or angioedema existed in either case. Swelling of the tongue 
and upper airways developed insidiously over a period of 8 
hours in both cases. In one case the subject died en route to 
hospital, and in the other case the subject arrived at hospital 
but died after a failed endotracheal intubation and delay in 
placement of a tracheostomy. Other causes of angioedema 
were excluded in both cases by reviewing the past medical 
history, the presentation, and the macro- and microscopic 
autopsy findings, including total IgE and mast cell tryptase 
levels (these were within normal reference values).
The cause of death in both cases was classified as unnatural.
Discussion
The use of ACE inhibitors is increasing and this could 
possibly lead to a concomitant increase in the incidence of 
ACE inhibitor-induced angioedema2 and other related side 
effects. Although the mechanism for ACE inhibitor-induced 
angioedema is not yet fully understood, it is postulated 
to be related to bradykinin and substance P metabolism.1 
Angioedema usually occurs most commonly during the 
first week of therapy, but can occur after months and even 
years of treatment.3 Studies have shown that the Black 
population may be at greater risk of angioedema, with an 
odds radio of 2.88 reported.4 The hypothesis is that since 
urinary kallikrein levels are decreased in Black patients with 
hypertension, they may have lower endogenous bradykinin 
levels, which may render them more susceptible to ACE 
inhibitor-induced increases in bradykinin and thus to the 
induction of angioedema.1
Recently, Cupido and Rayner reported on 12 cases of life-
threatening angioedema, with death resulting in four of 
these cases.4 They stressed their concern for the South 
African situation, where Blacks are the majority population 
and hence many patients will be Black, and at high risk of 
developing angioedema.
We strongly suspect that angioedema-associated 
airway obstruction due to ACE inhibitor therapy is an 
underdiagnosed cause of death, for the following possible 
reasons:
• Angioedema of the airways is erroneously attributed 
to an anaphylactic or anaphylactoid reaction, and the 
association between the condition and ACE inhibitor 
treatment is not readily made.
• Co-pathology often exists in these patients (e.g. heart 
failure, diabetes mellitus, hypertension), and the cause of 
death may be attributed to the co-pathology, rather than 
a side-effect of medication.
Clinical presentation of laryngeal oedema in a patient 
on ACE inhibitor treatment is an ominous sign and 
immediate securing of the airway (endotracheal/emergency 
surgical airway/tracheostomy) is mandatory as there 
is no other effective emergency treatment presently 
available3 Recommended long-term treatment includes 
drug withdrawal, and changing to a different class of 
medication.1,2,3
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We contend that, in the light of a probable increase in 
cases of death due to ACE inhibitor-induced angioedema,3 
patients should be informed of the possible severity of this 
side-effect and advised to urgently seek medical attention 
when symptoms develop. The use of this medication is 
contra-indicated in patients with a previous personal or 
family history of angioedema.1,5
Health workers need to recognise the existence of this life-
threatening complication and appreciate the importance 
of the referral of suspected cases to regional medico-legal 
laboratories for the performance of forensic autopsies, 
preferably by trained forensic pathologists, to confirm or 
exclude the diagnosis/cause of death. In cases where drug 
induced angioedema is confirmed as the mechanism of 
death, it should subsequently be reported to the Medicines 
Control Council of South Africa to ensure accurate recording 
of the number of cases. This will assist in ascertaining the 
incidence of this fatal complication in the South African 
population, and may facilitate further research and 
awareness in this field.
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